X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12824) 12824
Publication (1598) 1598
Newsletter (822) 822
Book Review (314) 314
Magazine Article (141) 141
Book Chapter (93) 93
Newspaper Article (70) 70
Transcript (24) 24
Conference Proceeding (16) 16
Book / eBook (11) 11
Trade Publication Article (8) 8
Dissertation (4) 4
Data Set (3) 3
Presentation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
corticosteroids (11414) 11414
index medicus (7951) 7951
humans (7585) 7585
male (4846) 4846
female (4417) 4417
animals (3728) 3728
steroids (2935) 2935
adult (2702) 2702
analysis (2637) 2637
middle aged (2078) 2078
neurosciences (1862) 1862
asthma (1826) 1826
pharmacology & pharmacy (1764) 1764
glucocorticoids (1533) 1533
stress (1533) 1533
research (1500) 1500
endocrinology & metabolism (1401) 1401
care and treatment (1393) 1393
immunology (1363) 1363
cortisol (1331) 1331
aged (1319) 1319
inflammation (1259) 1259
health aspects (1172) 1172
rats (1112) 1112
drug therapy (1095) 1095
medicine & public health (1091) 1091
physiological aspects (1086) 1086
adolescent (1081) 1081
treatment outcome (1068) 1068
psychiatry (1044) 1044
article (999) 999
asthma - drug therapy (970) 970
young adult (959) 959
mice (940) 940
inhaled corticosteroids (925) 925
risk factors (923) 923
dexamethasone (889) 889
child (860) 860
hormones (819) 819
gene expression (818) 818
allergy (805) 805
medical research (797) 797
children (784) 784
expression (777) 777
therapy (774) 774
respiratory system (771) 771
drugs (751) 751
internal medicine (708) 708
adrenal cortex hormones - therapeutic use (696) 696
glucocorticoids - pharmacology (674) 674
biochemistry & molecular biology (672) 672
medicine (671) 671
hydrocortisone - blood (666) 666
time factors (664) 664
double-blind (662) 662
brain (657) 657
dose-response relationship, drug (643) 643
medicine, experimental (638) 638
proteins (635) 635
administration, inhalation (630) 630
glucocorticoids - therapeutic use (624) 624
double-blind method (623) 623
studies (619) 619
research article (612) 612
dosage and administration (610) 610
cancer (606) 606
receptors, glucocorticoid - metabolism (598) 598
pregnancy (597) 597
cytokines (578) 578
cell biology (575) 575
patients (570) 570
hydrocortisone - metabolism (563) 563
pituitary-adrenal axis (541) 541
medical colleges (540) 540
clinical trials (537) 537
mortality (534) 534
disease (532) 532
dexamethasone - pharmacology (528) 528
pediatrics (526) 526
drug therapy, combination (525) 525
hydrocortisone (520) 520
physiology (518) 518
abridged index medicus (505) 505
rodents (502) 502
genetic aspects (500) 500
adrenal cortex hormones - administration & dosage (493) 493
gene-expression (488) 488
universities and colleges (488) 488
aldosterone (479) 479
corticoids (476) 476
behavioral sciences (475) 475
genes (473) 473
glucocorticoids - administration & dosage (471) 471
multidisciplinary sciences (465) 465
glucocorticoid receptor (464) 464
prednisone (463) 463
oncology (462) 462
depression (457) 457
corticosteroid (445) 445
prednisolone (443) 443
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13939) 13939
French (25) 25
German (11) 11
Japanese (3) 3
Spanish (3) 3
Polish (2) 2
Turkish (2) 2
Chinese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Clinical Pharmacology, ISSN 0306-5251, 10/2017, Volume 83, Issue 10, pp. 2148 - 2162
Aims Aprepitant and fosaprepitant, commonly used for the prevention of chemotherapy‐induced nausea and vomiting, alter cytochrome P450 activity. This... 
aprepitant | drug–drug interactions | fosaprepitant | METHYLENE-BLUE | CHEMOTHERAPY-INDUCED NAUSEA | SITE ADVERSE EVENTS | CYTOCHROME-P450 3A4 | IFOSFAMIDE | drug-drug interactions | CANCER-PATIENTS | CONCISE GUIDE | PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | INDUCED NEUROTOXICITY | RECEPTOR ANTAGONIST APREPITANT | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Nausea - chemically induced | Humans | Antineoplastic Agents - therapeutic use | Drug Interactions | Cytochrome P-450 CYP2C9 Inducers - pharmacology | Antiemetics - therapeutic use | Antineoplastic Agents - pharmacology | Vomiting - prevention & control | Morpholines - therapeutic use | Quetiapine Fumarate - pharmacology | Aprepitant | Oxycodone - therapeutic use | Oxycodone - pharmacology | Injection Site Reaction - etiology | Serotonin Uptake Inhibitors - therapeutic use | Morpholines - pharmacology | Quetiapine Fumarate - therapeutic use | Nausea - prevention & control | Vomiting - chemically induced | Ethanol - pharmacology | Serotonin and Noradrenaline Reuptake Inhibitors - pharmacology | Cytochrome P-450 CYP2C9 Inducers - therapeutic use | Serotonin and Noradrenaline Reuptake Inhibitors - therapeutic use | Cytochrome P-450 CYP3A Inhibitors - therapeutic use | Antiemetics - pharmacology | Complications and side effects | Anthracyclines | Chemotherapy | Corticosteroids | Gastrointestinal agents | Drug interactions | Nausea | Cancer | Index Medicus | Systematic Review and Meta–Analysis
Journal Article
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 05/2017, Volume 79, Issue 5, pp. 1051 - 1055
Journal Article
Addiction Biology, ISSN 1355-6215, 01/2009, Volume 14, Issue 1, pp. 43 - 64
A challenging question that continues unanswered in the field of addiction is why some individuals are more vulnerable to substance use disorders than others.... 
stress | glucocorticoids | Addiction | alcoholism | reward system | dopamine | Dopamine | Glucocorticoids | Reward system | Alcoholism | Stress | CONDITIONED PLACE PREFERENCE | BIOCHEMISTRY & MOLECULAR BIOLOGY | SUBSTANCE ABUSE | SINGLE-NUCLEOTIDE POLYMORPHISM | GLUCOCORTICOIDS IN-VIVO | INDUCED BEHAVIORAL SENSITIZATION | RECOMBINANT GABA(A) RECEPTOR | CORTICOTROPIN-RELEASING-FACTOR | POSITRON-EMISSION-TOMOGRAPHY | MU-OPIOID-RECEPTOR | INDUCED DOPAMINE RELEASE | PITUITARY-ADRENAL AXIS | Neural Pathways - drug effects | Humans | Macaca mulatta | Substance-Related Disorders - genetics | Arousal - drug effects | gamma-Aminobutyric Acid - physiology | Dopamine - physiology | Neural Pathways - physiopathology | Alcoholism - physiopathology | Alcoholism - psychology | Hypothalamo-Hypophyseal System - physiopathology | Cues | Allostasis - physiology | Hypothalamo-Hypophyseal System - drug effects | Pituitary-Adrenal System - physiopathology | Arousal - genetics | Self Medication | Pituitary-Adrenal System - drug effects | Brain - physiopathology | Glucocorticoids - blood | Rats | Allostasis - drug effects | Substance-Related Disorders - physiopathology | Brain - drug effects | Corticotropin-Releasing Hormone - physiology | Arousal - physiology | Animals | Substance-Related Disorders - psychology | Alcoholism - genetics | Polymorphism, Genetic - genetics | Mice | Street Drugs - toxicity | Reward | Stress, Psychological - complications | Stress, Psychological - physiopathology | Complications and side effects | Medical colleges | Care and treatment | Corticosteroids | Drug interactions | Illegal drugs | Clinical trials | Substance abuse | Index Medicus
Journal Article
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 1/2011, Volume 50, Issue 1, pp. 25 - 39
Etravirine (formerly TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against wild-type and NNRTI-resistant strains of HIV-1.... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Drug-interactions | Ribavirin, drug interactions | Antiepileptic-drugs, drug interactions | Simvastatin, drug interactions | Voriconazole, drug interactions | Dexamethasone, drug interactions | Fibric-acid-derivatives, drug interactions | Rifampicin, drug interactions | Opioid-analgesics, drug interactions | Antidepressants, drug interactions | Atorvastatin, drug interactions | Antiretrovirals, drug interactions | Anti-infectives, drug interactions | Histamine-H2-receptor-antagonists, drug interactions | Diazepam, drug interactions | Ketoconazole, drug interactions | Fluconazole, drug interactions | Hypericum, drug interactions | HMG-CoA-reductase-inhibitors, drug interactions | Oral-contraceptives, drug interactions | Sildenafil, drug interactions | Omeprazole, drug interactions | Buprenorphine, drug interactions | Rosuvastatin, drug interactions | Non-nucleoside-reverse-transcriptase-inhibitors, drug interactions | Type-5-cyclic-nucleotide- phosphodiesterase-inhibitors, drug interactions | Corticosteroids, drug interactions | Paroxetine, drug interactions | Fluoxetine, drug interactions | Rifapentine, drug interactions | Ethinylestradiolnorethisterone, drug interactions | Ranitidine, drug interactions | Etravirine, drug interactions | Antifungals, drug interactions | Digoxin, drug interactions | Warfarin, drug interactions | Methadone, drug interactions | Fluvastatin, drug interactions | Rifabutin, drug interactions | Sertraline, drug interactions | Azithromycin, drug interactions | Pharmacokinetics | Calcineurin-inhibitors, drug interactions | Itraconazole, drug interactions | Proton-pump-inhibitors, drug interactions | Clarithromycin, drug interactions | TRANSCRIPTASE INHIBITOR ETRAVIRINE | METABOLISM | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | HIV-NEGATIVE VOLUNTEERS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | HUMAN LIVER | PLACEBO-CONTROLLED TRIAL | 2 DIFFERENT FORMULATIONS | CLINICAL PHARMACOKINETICS | Reverse Transcriptase Inhibitors - adverse effects | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | Drug-Related Side Effects and Adverse Reactions | Humans | Pyridazines - pharmacokinetics | Drug Therapy, Combination | Pyridazines - adverse effects | Etravirine | Drug interactions | Physiological aspects | Dosage and administration | Research | Properties | Drug therapy | HIV infection
Journal Article